Chokri Ben Lamine: Strategic Decision Making in Hematology under Competing Risks
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Game theory in Hematology equals strategic decision-making under competing risks (disease vs toxicity vs cost vs time).
Core idea: optimize outcome when multiple players (tumor, host, physician, system) interact․
AML induction vs wait
- aggressive disease equals ‘move early’ (dominant strategy)
- frail pt equals delay/low-intensity leads to minimize loss (minimax)․
MRD-guided decisions
- MRD positive leads to escalate (allo-SCT)
- MRD negative leads to de-escalate
- dynamic strategy equals sequential game․
CAR-T vs bispecific vs SCT
- competing strategies with different payoffs (CR, toxicity, durability)
- choose based on patient fitness plus tumor biology leads to expected utility maximization․
GVHD vs GVL balance
- immunosuppression decrease GVHD but increase relapse
- optimal point equals Nash equilibrium between immune control and toxicity․
Anticoagulation in cancer thrombosis
- bleeding risk vs clot risk
- adjust dose/timing leads to risk-dominant strategy․
Transfusion thresholds (PBM)
- liberal vs restrictive
- restrictive often ‘dominant strategy’ leads to same outcomes, fewer risks․
Antibiotic use in FN
- overuse leads to resistance
- underuse leads to mortality
- stewardship equals repeated game with system-level payoff․
Clonal evolution (AML/CLL/MM)
- tumor adapts to therapy equals ‘evolutionary game’
- combination/sequencing prevents resistant clone dominance․
Resource allocation (ICU beds, CAR-T slots)
- prioritize pts with highest benefit probability
- utility plus fairness balance․
One-liner
Hematology decisions equals multi-step strategic games leads to best outcomes when timing, sequencing, and risk trade-offs are optimized.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week